GlassScriptPhysician profile
Jesse S Fishman
NPI 1801490081
$3,755.09
in general payments reported to CMS, 2019-2025
26 companies · $2,657 in 2025
The $2,657 reported for 2025 was more than what 96% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $21.94 · 2024: $1,076 · 2025: $2,657.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,689 · Education: $66.13.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,688.96 |
| Education | $66.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $635.58 | 2024-2025 | Fasenra, Tezspire, Breztri |
| Novartis Pharmaceuticals Corporation | $399.75 | 2025 | |
| Glaxosmithkline, LLC. | $390.03 | 2024-2025 | Nucala, Trelegy Ellipta |
| Regeneron Healthcare Solutions, INC. | $373.12 | 2024-2025 | Dupixent |
| Genentech USA, INC. | $226.72 | 2024-2025 | Xolair |
| Csl Behring | $214.56 | 2024-2025 | Andembry, Haegarda, Hizentra |
| Grifols USA, LLC | $167.78 | 2024-2025 | Prolastin-C Liquid, Xembify |
| Amgen INC. | $166.07 | 2024-2025 | Tezspire |
| Cycle Pharmaceuticals INC | $141.02 | 2025 | Sajazir |
| Biocryst US Sales Co., LLC | $132.88 | 2024-2025 | Orladeyo |
| Genzyme Corporation | $131.12 | 2024-2025 | |
| Ars Pharmaceuticals Operations, INC. | $119.59 | 2025 | Neffy |
| Ionis Pharmaceuticals, INC. | $94.27 | 2025 | Dawnzera |
| Lilly USA, LLC | $93.48 | 2024-2025 | Ebglyss |
| Incyte Corporation | $78.69 | 2024-2025 | Opzelura |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pharming Healthcare, INC. | $70.63 | 2024 | Ruconest |
| Galderma Laboratories, L.P. | $67.60 | 2025 | Nemluvio |
| Pfizer INC. | $66.94 | 2024-2025 | |
| Arcutis Biotherapeutics, INC. | $30.72 | 2025 | Zoryve |
| Takeda Pharmaceuticals U.S.A., INC. | $26.39 | 2024 | Hyqvia |
| Paratek Pharmaceuticals, INC. | $25.06 | 2025 | Xhance |
| Abbvie INC. | $24.09 | 2025 | |
| Inspire Medical Systems, INC. | $23.45 | 2024 | Inspire |
| Medtronic, INC. | $21.94 | 2023 | Kyphon Express II Kyphopak Tray |
| Optinose US, INC. | $17.38 | 2025 | |
| Phadia US INC. | $16.23 | 2025 | Immunocap |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jesse Fishman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.